A detailed history of Clarius Group, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Clarius Group, LLC holds 60,615 shares of BEAM stock, worth $1.53 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
60,615
Previous 60,615 -0.0%
Holding current value
$1.53 Million
Previous $1.42 Million 4.58%
% of portfolio
0.11%
Previous 0.1%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

BUY
$30.15 - $48.79 $979,995 - $1.59 Million
32,504 Added 115.63%
60,615 $1.86 Million
Q2 2022

Aug 10, 2022

BUY
$29.86 - $62.36 $759,071 - $1.59 Million
25,421 Added 945.02%
28,111 $1.09 Million
Q4 2021

Feb 02, 2022

SELL
$68.02 - $99.06 $2,720 - $3,962
-40 Reduced 1.47%
2,690 $214,000
Q3 2021

Oct 18, 2021

BUY
$84.37 - $133.6 $65,386 - $103,540
775 Added 39.64%
2,730 $238,000
Q2 2021

Aug 06, 2021

BUY
$64.12 - $128.71 $125,354 - $251,628
1,955 New
1,955 $252,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Clarius Group, LLC Portfolio

Follow Clarius Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clarius Group, LLC with notifications on news.